Edgewise Therapeutics, Inc.
EWTX
Classement en actions
#3859
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Prix de l'action
$39.70
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$4.27B
Changement (1 jour)
-0.12%
Changement (1 an)
166.64%
Pays
US
Échange Edgewise Therapeutics, Inc. (EWTX)
Catégorie
Healthcare
Historique du prix de l'action pour Edgewise Therapeutics, Inc. (EWTX)
Prix de clôture le plus élevé : $38.97 le 2026-10-01
Prix de clôture le plus bas : $32.43 le 2021-03-01
Prix de clôture le plus bas : $32.43 le 2021-03-01
Historique du prix de l'action de Edgewise Therapeutics, Inc. de 2021 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | 38.00% |
| 2025 | -20.97% |
| 2024 | 268.96% |
| 2023 | -1.80% |
| 2022 | -51.10% |
| 2021 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.24 | -4.19% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
